New drug shows promise in blocking kaposi sarcoma growth
NCT ID NCT02799485
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called sEphB4-HSA in 23 people with Kaposi sarcoma, a type of skin cancer. The drug works by stopping blood vessels from feeding the cancer and may also slow cancer cell growth. The goal was to see how many patients responded to treatment and to check for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KAPOSI SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Grady Health System
Atlanta, Georgia, 30303, United States
-
John H. Stroger Jr., Hospital of Cook County
Chicago, Illinois, 60612, United States
-
Johns Hopkins University
Baltimore, Maryland, 21205, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
UCLA CARE Center
Los Angeles, California, 90025, United States
-
UCSD Moores Cancer Center
La Jolla, California, 92093, United States
-
University of Miami
Miami, Florida, 33136, United States
-
Virginia Mason Medical Center
Seattle, Washington, 98101, United States
-
Washington University
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail targets rare, aggressive cancer
- Kaposi's sarcoma drug trial halted early – what we know
- Scientists seek tissue samples to unlock HIV-Cancer mysteries
- Can a smaller dose of this cancer drug still work? new trial aims to find out
- Experimental drug shows promise for kaposi sarcoma lesions
- New hope for rare cancers: immunotherapy drug targets tumors regardless of origin